Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
Recent INZY News
- Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference • GlobeNewswire Inc. • 08/29/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:54:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 08:52:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 12:41:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 12:39:04 PM
- Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights • GlobeNewswire Inc. • 08/06/2024 12:30:00 PM
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function • GlobeNewswire Inc. • 07/25/2024 12:30:00 PM
- Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency • GlobeNewswire Inc. • 07/02/2024 12:30:00 PM
- Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH) • GlobeNewswire Inc. • 06/21/2024 05:00:00 PM
- Inozyme Pharma to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:30:00 PM
- Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences • GlobeNewswire Inc. • 05/23/2024 12:30:00 PM
- Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference • GlobeNewswire Inc. • 05/08/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:33:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:32:27 PM
- Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights • GlobeNewswire Inc. • 05/07/2024 12:30:44 PM
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 12:30:02 PM
- Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency • GlobeNewswire Inc. • 04/08/2024 10:30:35 AM
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/05/2024 10:00:00 PM
- Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 12:30:03 PM
- Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 • GlobeNewswire Inc. • 03/26/2024 12:30:42 PM
- Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights • GlobeNewswire Inc. • 03/12/2024 12:30:16 PM
- Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:48:34 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/13/2024 02:06:26 AM
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/06/2024 01:30:48 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM